Full Text (PDF)
Review Article

Systemic Treatments: Is it making Cancer Patients more Vulnerable to COVID 19?

Shilpa Raghuvanshi Chauhan , Shilpa Raghuvanshi Chauhan

Author Information

Licence:




Journal of Global Public Health 3(1):p 23-26, January - June 2021. | DOI:

How Cite This Article:

Shilpa Raghuvanshi Chauhan/Systemic Treatments: Is it making Cancer Patients more Vulnerable to COVID 19/Journal of Global Public Health. 2021; 3(1): 23–26.


Timeline

Received : N/A         Accepted : N/A          Published : N/A

Abstract

COVID 19 caused by SARS-CoV-2 has spread across the globe claiming millions of life. However, many have survived after infection. There are multiple risk factors associated with the fatality of the disease like age, immunity, gender, diabetes, organ transplantation etc. Host immune response plays a critical role in control of infection and pathogenesis during this viral infection. Any treatment that modulate host immune response should be critically analysed before its implementation during this pandemic. Cancer patients receive systemic treatments to regress the tumor growth and have multiple side effects on host immune response. Little is known about the impact of such anticancer treatments on vulnerability, severity and mortality from COVID 19. This mini review focuses on the current literature and highlights the probable increase in risks for cancer patients receiving systemic anticancer treatments


References

No records found.


About this article


Cite this article

Shilpa Raghuvanshi Chauhan/Systemic Treatments: Is it making Cancer Patients more Vulnerable to COVID 19/Journal of Global Public Health. 2021; 3(1): 23–26.


Licence:




Received Accepted Published
N/A N/A N/A

DOI:

Keywords


Article Level Metrics

Last Updated

Saturday 05 September 2026, 13:29:59 (IST)


789

Accesses

8
120
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received N/A
Accepted N/A
Published N/A

licence



Access this article



Share